- RecruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This study is looking at new medicines (frexalimab, brivekimig, or rilzabrutinib) for kidney conditions called Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD). It aims to see if these medicines are safe and can help improve kidney function compared to a dummy drug.
For: Focal Segmental Glomerulosclerosis · Glomerulonephritis Minimal LesionUnited States · Argentina · Australia - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
For: Hidradenitis SuppurativaUnited States · Australia · Canada